8.4 C
London
Saturday, February 22, 2025
HomeMarketsEurope Markets

Europe Markets

spot_img

MicardisPlus | European Medicines Agency (EMA)

OverviewThis is a summary of the European public assessment report (EPAR) for MicardisPlus. It explains how the Committee for Medicinal Products for Human...

Kinzalkomb | European Medicines Agency (EMA)

OverviewThis is a summary of the European public assessment report (EPAR) for Kinzalkomb. It explains how the Committee for Medicinal Products for Human...

Opening procedures at EMA to non-EU authorities (OPEN) framework

Participating organisations The OPEN framework relies on permanent confidentiality...

Gavreto | European Medicines Agency (EMA)

OverviewThe marketing authorisation for Gavreto has been withdrawn at the request of the marketing-authorisation holder. ...

Mayzent | European Medicines Agency (EMA)

OverviewMayzent is a medicine used to treat adults with an advanced form of multiple sclerosis (MS) known as secondary progressive MS.It is used...

Vaxneuvance | European Medicines Agency (EMA)

OverviewVaxneuvance is a vaccine used to protect against three types of infections caused by the bacterium Streptococcus pneumoniae (S. pneumoniae):acute otitis media (ear...

Palforzia | European Medicines Agency (EMA)

OverviewPalforzia is a medicine for treating peanut allergy in children from 1 to 17 years of age and patients who become adults whilst...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read

spot_img